New modalities in the treatment of pregnancies complicated by diabetes: Drugs and devices

Lironn Chitayat; Lois Jovanovic; Moshe Hod

doi:10.1016/j.siny.2008.09.001

New modalities in the treatment of pregnancies complicated by diabetes: Drugs and devices

Lironn Chitayat, Lois Jovanovic^*, Moshe Hod

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

The development of drugs and devices in the treatment of pregnancies complicated by diabetes is in constant forward progression to compensate for pancreatic beta cell insufficiency. Maternal hyperglycemia during pregnancy is of particular interest due to the severe consequences that surface when a fetus is in development. The drugs that are currently recommended for use during pregnancy include rapid-acting insulin analogs lispro and aspart for meal-related bolus insulin and intermediate-acting NPH for basal insulin. Oral anti-diabetic agents are not recommended for use during pregnancy. Better control may be achieved with the incorporation of real-time glucose sensors and new insulin pumps with hopes of improving pregnancy outcome.

Original language	English
Pages (from-to)	72-76
Number of pages	5
Journal	Seminars in Fetal and Neonatal Medicine
Volume	14
Issue number	2
DOIs	https://doi.org/10.1016/j.siny.2008.09.001
State	Published - Apr 2009
Externally published	Yes

Keywords

Artificial pancreas
Diabetes mellitus
Glucose monitoring
Glyburide
Insulin
Metformin
Pregnancy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.siny.2008.09.001

Cite this

@article{7437e82ee9504f70bfeb7f7661619610,

title = "New modalities in the treatment of pregnancies complicated by diabetes: Drugs and devices",

abstract = "The development of drugs and devices in the treatment of pregnancies complicated by diabetes is in constant forward progression to compensate for pancreatic beta cell insufficiency. Maternal hyperglycemia during pregnancy is of particular interest due to the severe consequences that surface when a fetus is in development. The drugs that are currently recommended for use during pregnancy include rapid-acting insulin analogs lispro and aspart for meal-related bolus insulin and intermediate-acting NPH for basal insulin. Oral anti-diabetic agents are not recommended for use during pregnancy. Better control may be achieved with the incorporation of real-time glucose sensors and new insulin pumps with hopes of improving pregnancy outcome.",

keywords = "Artificial pancreas, Diabetes mellitus, Glucose monitoring, Glyburide, Insulin, Metformin, Pregnancy",

author = "Lironn Chitayat and Lois Jovanovic and Moshe Hod",

year = "2009",

month = apr,

doi = "10.1016/j.siny.2008.09.001",

language = "אנגלית",

volume = "14",

pages = "72--76",

journal = "Seminars in Fetal and Neonatal Medicine",

issn = "1744-165X",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - New modalities in the treatment of pregnancies complicated by diabetes

T2 - Drugs and devices

AU - Chitayat, Lironn

AU - Jovanovic, Lois

AU - Hod, Moshe

PY - 2009/4

Y1 - 2009/4

N2 - The development of drugs and devices in the treatment of pregnancies complicated by diabetes is in constant forward progression to compensate for pancreatic beta cell insufficiency. Maternal hyperglycemia during pregnancy is of particular interest due to the severe consequences that surface when a fetus is in development. The drugs that are currently recommended for use during pregnancy include rapid-acting insulin analogs lispro and aspart for meal-related bolus insulin and intermediate-acting NPH for basal insulin. Oral anti-diabetic agents are not recommended for use during pregnancy. Better control may be achieved with the incorporation of real-time glucose sensors and new insulin pumps with hopes of improving pregnancy outcome.

AB - The development of drugs and devices in the treatment of pregnancies complicated by diabetes is in constant forward progression to compensate for pancreatic beta cell insufficiency. Maternal hyperglycemia during pregnancy is of particular interest due to the severe consequences that surface when a fetus is in development. The drugs that are currently recommended for use during pregnancy include rapid-acting insulin analogs lispro and aspart for meal-related bolus insulin and intermediate-acting NPH for basal insulin. Oral anti-diabetic agents are not recommended for use during pregnancy. Better control may be achieved with the incorporation of real-time glucose sensors and new insulin pumps with hopes of improving pregnancy outcome.

KW - Artificial pancreas

KW - Diabetes mellitus

KW - Glucose monitoring

KW - Glyburide

KW - Insulin

KW - Metformin

KW - Pregnancy

UR - http://www.scopus.com/inward/record.url?scp=60549093195&partnerID=8YFLogxK

U2 - 10.1016/j.siny.2008.09.001

DO - 10.1016/j.siny.2008.09.001

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

AN - SCOPUS:60549093195

SN - 1744-165X

VL - 14

SP - 72

EP - 76

JO - Seminars in Fetal and Neonatal Medicine

JF - Seminars in Fetal and Neonatal Medicine

IS - 2

ER -

New modalities in the treatment of pregnancies complicated by diabetes: Drugs and devices

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this